258 related articles for article (PubMed ID: 18758125)
1. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease.
Sawara Y; Takei T; Uchida K; Ogawa T; Yoshida T; Tsuchiya K; Nitta K
Intern Med; 2008; 47(17):1505-10. PubMed ID: 18758125
[TBL] [Abstract][Full Text] [Related]
2. Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease.
Abe M; Maruyama N; Yoshida Y; Ito M; Okada K; Soma M
Endocr J; 2011; 58(8):663-74. PubMed ID: 21670545
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study.
Riccioni G; Bazzano LA; Bucciarelli T; Mancini B; di Ilio E; D'Orazio N
Expert Opin Pharmacother; 2008 Oct; 9(14):2403-8. PubMed ID: 18778179
[TBL] [Abstract][Full Text] [Related]
4. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
J Atheroscler Thromb; 2011; 18(11):1018-28. PubMed ID: 21921413
[TBL] [Abstract][Full Text] [Related]
5. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.
Yamazaki D; Ishida M; Watanabe H; Nobori K; Oguma Y; Terata Y; Koyama T; Iino K; Kosaka T; Ito H
Lipids Health Dis; 2013 Feb; 12():9. PubMed ID: 23374898
[TBL] [Abstract][Full Text] [Related]
6. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein lowering with rosuvastatin in the METEOR study.
Peters SA; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Raichlen JS; Bots ML
J Intern Med; 2010 Aug; 268(2):155-61. PubMed ID: 20412373
[TBL] [Abstract][Full Text] [Related]
8. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.
Ferdinand KC
Expert Opin Pharmacother; 2005 Sep; 6(11):1897-910. PubMed ID: 16144509
[TBL] [Abstract][Full Text] [Related]
10. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
11. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
14. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
15. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
16. Prevention of atherosclerosis in patients living with HIV.
De Lorenzo F; Boffito M; Collot-Teixeira S; Gazzard B; McGregor JL; Shotliff K; Xiao H
Vasc Health Risk Manag; 2009; 5(1):287-300. PubMed ID: 19436663
[TBL] [Abstract][Full Text] [Related]
17. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
18. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial.
Tam LS; Li EK; Shang Q; Tomlinson B; Lee VW; Lee KK; Li M; Kuan WP; Li TK; Tseung L; Yip GW; Freedman B; Yu CM
Scand J Rheumatol; 2011 Nov; 40(6):411-21. PubMed ID: 21867445
[TBL] [Abstract][Full Text] [Related]
19. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.
Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yokoi H; Yoshida M;
Circ J; 2012; 76(1):221-9. PubMed ID: 22094911
[TBL] [Abstract][Full Text] [Related]
20. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study.
Crouse JR; Grobbee DE; O'Leary DH; Bots ML; Evans GW; Palmer MK; Riley WA; Raichlen JS;
Cardiovasc Drugs Ther; 2004 May; 18(3):231-8. PubMed ID: 15229392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
